Monitoring the quality of laboratories and the prevalence of resistance to antituberculosis drugs: Italy, 1998-2000 Source: Eur Respir J 2003; 21: 129-134 Year: 2003
Adverse drug reactions to second line anti tuberculosis drugs: A prospective study in Mumbai, India Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Treatment outcome of 35 MDR TB patients with 2nd line drugs - a three year follow up report; Hyderabad, India Source: Eur Respir J 2005; 26: Suppl. 49, 651s Year: 2005
Trend of acquired drug resistance to main anti TB drugs in the first 7 years of applying DOT strategy in Iasi County, Romania Source: Annual Congress 2007 - Tuberculosis control Year: 2007
Is it possible to achieve treatment success, recommended by WHO in country with high level of multidrug resistant TB? Source: Eur Respir J 2001; 18: Suppl. 33, 338s Year: 2001
Rifampicin (Rif)-resistant tuberculosis (TB) on GeneXpert in Mumbai, India: How effective is the best derived empiric regimen? Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
The problem of multi-drug resistant (MDR)-TB Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties Year: 2005
Multicentre randomised clinic study of new standard chemotherapy regimen for new cases patients of pulmonary tuberculosis executed in Russia regions with high level of multiple drug resistance (MDR) Source: Annual Congress 2009 - Tuberculosis control Year: 2009
Rifampicin-resistant tuberculosis: what is the best initial empiric regimen in Mumbai, India? Source: Eur Respir J, 50 (1) 1602182; 10.1183/13993003.02182-2016 Year: 2017
Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Frequency of side effects among patients with drug resistant tuberculosis (DR-TB) by resistance pattern in a high burden country. Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020
New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
Frequency of drug resistance and treatment results in patients with newly detected tuberculosis using standard chemotherapeutical regimen on the data of district hospital, Kiev Source: Eur Respir J 2002; 20: Suppl. 38, 402s Year: 2002
Frequency of drug resistance and treatment results with standard chemotherapeutical regimen in patients with newly detected tuberculosis on the data of district hospital, Kiev Source: Eur Respir J 2002; 20: Suppl. 38, 548s Year: 2002
When, where, and how to treat tuberculosis in multiple drug resistant patients Source: International Congress 2016 – PG10 Tuberculosis management: a personalised clinical approach Year: 2016
First line anti-tuberculous drug resistance prevalence and its pattern among HIV infected patients in the national referral TB center, Iran Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009
Investigating trends in antituberculosis (anti-TB) drug resistance among treated patients of a university respiratory infections unit in Greece Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India Source: Eur Respir J , 49 (3) 1601699; DOI: 10.1183/13993003.01699-2016 Year: 2017
Dynamics analysis of MBT drug resistance to antitubercolosis second-line drugs (Saratov region hospital, Russia) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Multi-drug resistant tuberculosis (MDR-TB) in Ramnicul Valcear, Romania; drug treatment, resistance testing and adverse drug reactions Source: Eur Respir J 2006; 28: Suppl. 50, 378s Year: 2006